Technical Analysis for CRDF - Cardiff Oncology, Inc.

Grade Last Price % Change Price Change
B 5.17 2.78% 0.14
CRDF closed up 2.78 percent on Monday, March 18, 2024, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Wide Range Bar Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Slingshot Bullish Bullish Swing Setup 2.78%
Wide Bands Range Expansion 2.78%
Overbought Stochastic Strength 2.78%
Calm After Storm Range Contraction -4.26%
New 52 Week High Strength -4.26%
Parabolic Rise Strength -4.26%

   Recent Intraday Alerts

Alert Time
Up 5% about 17 hours ago
Up 3% about 17 hours ago
Up 2% about 17 hours ago
60 Minute Opening Range Breakout about 17 hours ago
Reversed from Down about 17 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cardiff Oncology, Inc. Description

Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Pharmaceutical Solid Tumors Drugs Cancer Treatment Oncology Lymphoma Phosphates Acute Myeloid Leukemia Chemotherapy Prostate Cancer Antineoplastic Drugs Colorectal Cancer Leukemia Targeted Therapy Advanced Solid Tumors Solid Tumor Cancers Adenosine Resistant Prostate Cancer Metastatic Castration Resistant Prostate Cancer Metastatic Colorectal Cancer Nektar Therapeutics

Is CRDF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.06
52 Week Low 0.94
Average Volume 1,791,634
200-Day Moving Average 1.67
50-Day Moving Average 2.28
20-Day Moving Average 3.25
10-Day Moving Average 4.47
Average True Range 0.58
RSI (14) 78.35
ADX 50.14
+DI 33.37
-DI 13.65
Chandelier Exit (Long, 3 ATRs) 4.31
Chandelier Exit (Short, 3 ATRs) 3.40
Upper Bollinger Bands 6.02
Lower Bollinger Band 0.47
Percent B (%b) 0.85
BandWidth 170.78
MACD Line 0.91
MACD Signal Line 0.69
MACD Histogram 0.2137
Fundamentals Value
Market Cap 230.98 Million
Num Shares 44.7 Million
EPS -0.92
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Sales 174.60
Price-to-Book 1.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.97
Resistance 3 (R3) 6.85 6.12 6.67
Resistance 2 (R2) 6.12 5.66 6.19 6.57
Resistance 1 (R1) 5.65 5.38 5.89 5.77 6.47
Pivot Point 4.92 4.92 5.04 4.99 4.92
Support 1 (S1) 4.45 4.46 4.69 4.57 3.87
Support 2 (S2) 3.72 4.18 3.79 3.77
Support 3 (S3) 3.25 3.72 3.67
Support 4 (S4) 3.37